Trividia Health Announces Jonathan Chapman as President and Chief Executive Officer
Trividia Health, Inc., a leading supplier of blood glucose monitoring systems, announced today that Jonathan Chapman has been appointed as President and Chief Executive Officer. Mr. Chapman succeeds Scott Verner in the role.
Mr. Chapman brings over 20 years of leadership experience in the medical device industry, with an accomplished track record of driving growth, developing strategic alliances, launching products globally, and optimizing business operations.
In addition to his newly assumed responsibilities at Trividia Health, Mr. Chapman will continue to serve as President and Chief Executive Officer of PTS Diagnostics, Inc.
“Jonathan has proven himself as the right leader for PTS Diagnostics and is the right leader for Trividia,” said Shaobo Li, Chairman of the Board at both Trividia Health and PTS Diagnostics. “Jonathan’s extensive background in successfully running medical device companies and his business development skills will help both organizations to reach the next level of growth and evolution. Jonathan is a results-oriented, dynamic, and innovative business leader. I am confident he has the right track record, commitment, vision and judgment to lead Trividia and PTS Diagnostics.”
“I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes,” said Jonathan Chapman, President and CEO of Trividia Health and PTS Diagnostics. “I look forward to working with my colleagues at Trividia. With their support, focus on customers and continuing dedication, we will build on Trividia’s legacy of bringing leading innovation to patients across the globe.”
Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. Trividia is confident that his international experience will be immensely valuable when leading the organization across global markets.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company with over 30 years experience in the industry. Based in Fort Lauderdale, Florida, Trividia is a leading developer, manufacturer and marketer of advanced performance products for people and pets with diabetes. With products sold under the TRUE brand, store brand labels and Healthy Tracks for Pets, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005226/en/
Contact information
Neal Bhattacharya, Sr. Director, Product Marketing
(800) 342-7226, ext. 3150 – nbhattacharya@trividiahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone Credit & Insurance Appoints Laura Coady as Global Head of CLOs and European Head of Liquid Credit Strategies3.11.2025 14:10:00 EET | Press release
Blackstone (NYSE: BX) announced today that Laura Coady, formerly Head of International Securitised Markets and Global Head of CLOs at Jefferies, has joined Blackstone Credit & Insurance (“BXCI”) as Global Head of CLOs and European Head of Liquid Credit Strategies (LCS). Based in London, Coady will oversee BXCI’s CLO activity globally, including CLO formation and investing, and lead the liquid credit business in Europe. BXCI’s LCS business manages $120 billion across corporate bonds, leveraged loans, CLOs and Multi-Asset Credit. Blackstone is the largest global manager of CLOs and loans, and the most active loan trader. The firm set a record for global annual CLO issuance in 2024, beating the previous record set by Blackstone in 2021. Dan Leiter, Head of International and Global Head of Liquid Credit Strategies for BXCI, said: “We’re thrilled to welcome Laura to further strengthen our global CLO franchise and expand our liquids business across Europe. We believe our momentum in these ar
AMINA Becomes the First Crypto Banking Group to Receive a MiCA License Through Its Austrian Subsidiary3.11.2025 14:04:00 EET | Press release
AMINA Bank AG (“AMINA Bank”) today announced that its newly established subsidiary, AMINA (Austria) AG (“AMINA EU”), has received a Crypto-Asset Service Provider (CASP) license from Austria’s Financial Market Authority (FMA) under the Markets in Crypto-Assets (MiCAR) framework. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103510417/en/ AMINA Expands into the EU The FMA’s approval paves the way for AMINA EU’s launch, with regulated crypto trading, custody, and portfolio management services, as well as crypto staking, to be introduced at launch. These offerings will be available to professional investors, including family offices, corporates, financial institutions, and more. AMINA EU, an FMA-licensed crypto-asset service provider, will offer a purpose-built platform giving clients secure, institutional-grade access to the crypto ecosystem. As a wholly owned subsidiary of AMINA Bank and a member of the global AMINA Group,
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation3.11.2025 14:02:00 EET | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience, making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103162356/en/ TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP,
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization3.11.2025 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications in multiple countries worldwide, which could simplify vaccination schedules and increase adherence. “We are seeing an unprecedented surge in dengue, with over 14 million cases reported across more than 100 countries in 2024 alone, largely driven by the impacts of climate change and inadequate urbanization. Brazil, consistently among the countries most impacted by dengue, has contributed to the record-breaking number of dengue cases and rise in severity and deaths. This surge highlights the urgent ne
SK Capital Completes Acquisition of LISI Group’s Medical Division and Launches New Platform as Precera Medical3.11.2025 13:30:00 EET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company. Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications including surgical robotics, minimally invasive surge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom